Föreläsningar och seminarier OnkPat Friday Seminar: Targeted drug delivery using engineered scaffold proteins for theranostics of cancer
Välkommen till OnkPat Friday Seminar med Anzhelika Vorobyeva från institutionen för immunologi, genetik och patologi vid Uppsala universitet.
Värd: Thuy Tran
Läs mer om Anzhelika Vorobyeva på den engelska sidan
Selected publications
Imaging of ROR1 expression in tumors using radiolabeled affibody molecules.
Westerberg C, Xu T, Marth M, Ud-Din M, Abushaia R, Hagelin T, Ståhl S, Orlova A, Tolmachev V, Löfblom J, Vorobyeva A
Eur J Nucl Med Mol Imaging 2026 Aug;():
Integrating Tumor Targeting and Half-Life Extension into a Dual-Surfaced Single-Domain ADAPT Protein.
Larsson E, Ud-Din M, Bitzios A, Recasens Pérez-Vera E, Tegel H, Orlova A, Tolmachev V, Vorobyeva A, Hober S
Mol Pharm 2026 Sep;23(9):4743-4757
Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
Zhang J, Bodenko V, Larkina M, Bezverkhniaia E, Xu T, Liao Y, Abouzayed A, Plotnikov E, Tretyakova M, Yuldasheva F, Belousov MV, Orlova A, Tolmachev V, Gräslund T, Vorobyeva A
J Control Release 2024 Jun;370():468-478
Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs.
Yin W, Xu T, Ding H, Zhang J, Bodenko V, Tretyakova MS, Belousov MV, Liu Y, Oroujeni M, Orlova A, Tolmachev V, Gräslund T, Vorobyeva A
J Control Release 2023 Mar;355():515-527
Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer.
Bragina O, Chernov V, Schulga A, Konovalova E, Garbukov E, Vorobyeva A, Orlova A, Tashireva L, Sörensen J, Zelchan R, Medvedeva A, Deyev S, Tolmachev V
J Nucl Med 2022 Apr;63(4):528-535